Johnson & Johnson push elderly drug after warning

Johnson & Johnson made plans to reach $302 million in geriatric sales for its antipsychotic Risperdal just months after federal regulators said the company falsely claimed the drug was safe and effective with the elderly, according to internal documents.

Read Bloomberg article

Posted in: Uncategorized

Leave a Reply